<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143386</url>
  </required_header>
  <id_info>
    <org_study_id>283T10</org_study_id>
    <nct_id>NCT04143386</nct_id>
  </id_info>
  <brief_title>Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease</brief_title>
  <acronym>PREDICTOR</acronym>
  <official_title>Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Estonian Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late stage lower extremity arterial disease (LEAD) is known to be associated with hemodynamic&#xD;
      and metabolic abnormalities and very poor long-term prognosis. The prognostic value of&#xD;
      hemodynamic and metabolic profiling, however, is yet to be determined in this patient group.&#xD;
&#xD;
      Current study aims to identify novel prognostic biomarkers for better risk stratification of&#xD;
      late stage LEAD patients. It also allows to determine associations between&#xD;
      hemodynamic/arterial stiffness indices, low-molecular weight metabolites and other substances&#xD;
      (e.g. mediators of inflammation and bone-mineral metabolism, cardiac and kidney injury&#xD;
      biomarkers, microRNAs) thus providing potentially valuable insight into the pathogenic&#xD;
      mechanisms of this disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of major adverse cardiovascular events, major adverse limb events and deaths</measure>
    <time_frame>5 years</time_frame>
    <description>A composite of any of the following events, as documented by patients' hospital or death records:&#xD;
nonfatal myocardial infarction or stroke&#xD;
fatal myocardial infarction or stroke&#xD;
hospitalization for angioplasty or bypass surgery for coronary or peripheral vessel disease&#xD;
LEAD-related major lower extremity amputation&#xD;
other cardiovascular deaths (cardiac arrest, lethal arrhythmia, heart failure, aortic dissection or rupture)&#xD;
non-cardiovascular deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of fatal cardiovascular events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-fatal cardiovascular events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of LEAD-related major lower extremity amputations</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for angioplasty or bypass surgery for coronary or peripheral vessel disease</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths from all causes</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Lower Extremity Arterial Disease (Fontaine Stages IIb-IV)</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptomatic lower extremity arterial disease referred to Tartu University&#xD;
        Hospital for revascularization (angioplasty/stenting or bypass surgery).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria:&#xD;
&#xD;
          -  Fontaine stage I-IIa;&#xD;
&#xD;
          -  acute limb ischemia;&#xD;
&#xD;
          -  age &lt;35 or &gt;85 years;&#xD;
&#xD;
          -  fasting &lt; 6 hours;&#xD;
&#xD;
          -  time since the last use of tobacco products &lt; 4 hours;&#xD;
&#xD;
          -  body mass index ≥ 40 kg/m2&#xD;
&#xD;
          -  blood pressure ≥ 180/120mmHg;&#xD;
&#xD;
          -  unstable angina;&#xD;
&#xD;
          -  atrial fibrillation at the time of presentation;&#xD;
&#xD;
          -  myocardial infarction, stroke or TIA during the preceding 3 months;&#xD;
&#xD;
          -  any revascularization during the preceding 1 month;&#xD;
&#xD;
          -  severe heart failure (NYHA IV);&#xD;
&#xD;
          -  clinically significant heart valve disease;&#xD;
&#xD;
          -  severe physical disability (other than limb ischemia);&#xD;
&#xD;
          -  acute infectious disease;&#xD;
&#xD;
          -  active malignancy or chemotherapy or disease-free &lt; 5 years;&#xD;
&#xD;
          -  type 1 diabetes;&#xD;
&#xD;
          -  uncompensated thyrotoxicosis/hypothyroidism or other clinically significant endocrine&#xD;
             disorders;&#xD;
&#xD;
          -  moderate to severe asthma (GINA 2016);&#xD;
&#xD;
          -  severe chronic obstructive pulmonary disease (mMRC grade 3-4)&#xD;
&#xD;
          -  acute (KDIGO 2012) or chronic renal disease (eGFR-EPI &lt;30mL/min/1.73 m2);&#xD;
&#xD;
          -  clinically significant acute or chronic liver disease;&#xD;
&#xD;
          -  severe anemia (&lt;80 g/L);&#xD;
&#xD;
          -  clinically significant neuroinflammatory or neurodegenerative disease;&#xD;
&#xD;
          -  active rheumatism;&#xD;
&#xD;
          -  clinically significant connective tissue disease;&#xD;
&#xD;
          -  alcoholism or drug abuse;&#xD;
&#xD;
          -  psychotic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jaak Kals, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaan Eha, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mihkel Zilmer, dr. med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaido Paapstel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaspar Tootsi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Kuusik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuljo Ööbik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riina Kaur</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaak Kals, MD, PhD</last_name>
    <phone>+372 731 8292</phone>
    <email>jaak.kals@kliinikum.ee</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaido Paapstel, MD, PhD</last_name>
    <phone>+372 731 8317</phone>
    <email>kaido.paapstel@kliinikum.ee</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaak Kals, MD, PhD</last_name>
      <phone>+372 731 8292</phone>
      <email>jaak.kals@kliinikum.ee</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <link>
    <url>https://endothelialcentre.ut.ee/</url>
    <description>Endothelial Research Centre</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Jaak Kals</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lower extremity arterial disease</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>metabolism</keyword>
  <keyword>metabolomics</keyword>
  <keyword>inflammation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>biomarkers</keyword>
  <keyword>prognosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

